Abstract: Malignant tumors that are intrinsically resistant to conventional therapies are significant therapeutic challenges. An embodiment of the present invention provides an oncolytic virus capable of killing target cells, such as a tumor cells. In various embodiments presented herein, the oncolytic virus is armed or encodes a therapeutic polypeptide. In at least one embodiment, a recombinant oncolytic virus has been generated that can specifically replicate in cancer cells leading to their destruction and at the same time secrete robust amounts of a therapeutic polypeptide. Compositions and methods disclosed herein have broad therapeutic applicability.

Abstract: Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.

Abstract: Methods and compositions for the diagnosis, prognosis and/or treatment of prostate associated disorders are disclosed.

Abstract: A method for producing nanocomposite particles is provided. The method comprises supplying an organic phase fluid an organic phase fluid, an aqueous phase fluid, an amphiphile, and a plurality of hydrophobic nanospecies to a nozzle. An electric field is generated proximate the nozzle such that the fluid exiting the nozzle forms a cone jet that disperses into a plurality of droplets. The plurality of droplets are collected, and nanocomposite particles comprising a self-assembled structure encapsulating at least one hydrophobic nanospecies form by self-assembly.